Sergey S. Usatyuk

Sergey S. Usatyuk

Auto-generated profile, based on publicly available information

Sergey S. Usatyuk

Moscow City Clinical Hospital №52

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
EVE.V. Volodina
E.V. Volodina
NFN.F. Frolova
N.F. Frolova
MLM.A. Lysenko
M.A. Lysenko
IKI.G. Kim
I.G. Kim
AUA.I. Ushakova
A.I. Ushakova
SASt. Petersburg S.M. Kirov Military Medical Academy
St. Petersburg S.M. Kirov Military Medical Academy
Применение нейтрализующих моноклональных антител при SARS-CoV-2-инфекции у больных, получающих лечение гемодиализом

15 November 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MZM L Zubkin
M L Zubkin
NFN F Frolova
N F Frolova
IKI G Kim
I G Kim
AUA I Ushakova
A I Ushakova
SUS S Usatiuk
S S Usatiuk
EKE V Kryukov
E V Kryukov
Background. Present concepts of the novel coronavirus infection prognosis in haemodialysis (HD) patients are rather controversial. There is little information on therapy efficiency and safety in such patients. We studied COVID-19 course specifics, prognostic factors associated with fatal outcomes, therapy efficiency and its transformation at different stages of the pandemic first year. Materials and methods. Single-centre retrospective uncontrolled study included 653 COVID-19 HD-patients treated at Moscow City Nephrology Centre from April 1 to December 31, 2020. Results. This period mortality rate was 21.0%. Independent predictors of COVID-19 unfavourable outcome in HD patients were pulmonary lesion extension (CT grades 34), high comorbidity index, and mechanical ventilation. Approaches to COVID-19 treatment modified significantly at different periods. Immunomodulatory drugs (monoclonal antibodies to IL-6, corticosteroids) were used largely at later stages. With tocilizumab administration, mortality was 15.1%, tocilizumab together with dexamethasone 13.3%; without them 37.8% (р0,001). Tocilizumab administration in the first 3 days after hospitalization of patients with CT grades 12 was associated with more favourable outcomes: 1 out of 29 died vs 6 out of 20 (tocilizumab administered at later periods); p0.04. There was no significant difference in death frequency in patients with CT grades 34 depending on tocilizumab administration time. Conclusion. COVID-19 in HD patients can manifest in a severe course with unfavourable outcome. It is urgent to identify reliable disease outcome predictors and develop efficient treatment in this population.

23 May 2025 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
TMT. N. Markova
T. N. Markova
VYV. O. Yavorskaya
V. O. Yavorskaya
AUA. I. Ushakova
A. I. Ushakova
ВБВ. А. Бердинский
В. А. Бердинский
TIT. V. Ibragimova
T. V. Ibragimova
SUS. S. Usatiuk
S. S. Usatiuk
BACKGROUND: Dialysis treatment is a risk factor for the development of carbohydrate metabolism disorders (CMD) and glycemia variability (VG) in patients with chronic kidney disease (CKD).AIM: To analyse the impact of renal replacement therapy (RRT) on the development of CMD in patients with CKD without a history of diabetes mellitus (DM).MATERIALS AND METHODS: 90 patients were examined with CKD without DM in the history (60 patients with CKD on RRT using program hemodialysis (pHD) and continuous ambulatory peritoneal dialysis (CAPD) and 30 patients with CKD 3–5 (without RRT)). Patients were collected anamnesis, measured the level of glycated hemoglobin (HbA1c), fasting plasma glucose (FPG) and capillary blood glucose at 5 points in the HD and advanced CKD stages groups and at 9 points in the CAPD group. Indices of VG and dynamics of the glucose median for Friedman in all groups were evaluated. Patients with impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), IGT and FPG, with first diagnosed DM were included in the CMD.RESULTS: In the total group (n=90), the median HbA1с was 5,1 [4,9; 5,4] %, median FPG was 5,2 [4,72; 5,94] mmol/L, and median postprandial glycemia (PPG) was 6,0 [5,5; 6,8] mmol/L. 32,2% (n=29) patients of the total group had CMD: first-diagnosed DM — 2,2% (2 patients), IFG and IGT — 3,3% (3 patients), IFG — 17,8% (16 patients), IGT — 8,9% (8 patients). The prevalence of CMD in the total group was higher according to FPG and/or PPG level than according to HbA1c value (31,3% vs 10%, p<0,001). 33,3% of patients on RRT had CMD; in the group with CKD without RRT, CMD was detected in 30% of patients (p=0,025). CMD were more frequent in patients on CAPD than in patients on pHD (46,7% vs 20%, p=0,028), mainly due to IFG. Patients with CKD on pHD, compared to patients on CAPD, showed a propensity for hypoglycemia as measured by the LBGI index (0,67±0,17 vs 1,66±0,67), p<0,001.CONCLUSION: A high prevalence of CKD was found in patients with CKD — 32,2%. Patients with CKD on RRT, compared to the group with advanced stage CKD without dialysis, have a higher incidence of CMD due to IFG and are prone to hypoglycemia development (group on pHD). A high VG within the groups was revealed regardless of the type of RRT, presence of advanced stages of CKD, day of dialysis.

5 March 2024 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
PDF file
TMT. N. Markova
T. N. Markova
VYV. O. Yavorskaya
V. O. Yavorskaya
AUA. I. Ushakova
A. I. Ushakova
ВБВ. А. Бердинский
В. А. Бердинский
TIT. V. Ibragimova
T. V. Ibragimova
SUS. S. Usatiuk
S. S. Usatiuk
Background. Patients with diabetes mellitus (DM) on renal replacement therapy (RRT) have high glycaemia variability (GV), the severity of which may depend on the dialysis method.The aim: To study GV in patients with type 1 diabetes and type 2 diabetes (on baseline-bolus insulin therapy) receiving RRT with programmed hemodialysis (PHD) and continuous ambulatory peritoneal dialysis (CAPD).Patients and Methods: Twenty-seven patients with terminal chronic renal failure and DM receiving RRT from July 2022 to March 2023 were studied. Patients underwent flash glucose monitoring (FGM) using FreeStyle Librе portable system with further evaluation of GV parameters and indices, median days of measurement – 14.Results. In the total group, 7 patients (23,3 %) had TIR > 70 %, mean TIR value was 56,3 %±22,0 %, 66,7 % of patients had CV > 36 %, mean CV value was 38,5 %±9,6 %. All indices of GV (MAGE, LBGI, HBGI, M-value, J-index, Conga, LI) exceeded the reference values. When comparing GV indices in patients on PHD and CAPD, it was revealed that LBGI in PHD group was 10,1±5,71 vs CAPD – 5,58±4,22, p=0,025. The critical point of glucose reduction on PHD was the fourth hour from the beginning of the procedure (57.1 % of patients had glycemia < 3.9 mmol/l). Higher median glucose values were found in the first three days of FGM compared to the last three days in both PHD group (p=0.002) and CAPD group (p=0.022).Conclusions. Patients with diabetes on RRT have high GV, low percentage of achieving TIR due to high risk of hypoglycemic conditions in patients on PHD. The critical point of glycaemia reduction is fourth hour after the start of the PHD session. Patients on CAPD have a lower risk of hypoglycemia. FGM improves glycaemic control.